GSK announces strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases

The programme will cover 5000 COPD patients and 60,000 athma patients.

 

GSK today announced it will form a strategic partnership with Guangzhou Institute of Respiratory Diseases (GIRD). The strategic collaboration will focus on respiratory disease management system, including asthma and chronic obstructive pulmonary disease (COPD), and health big data system will be developed through information sharing and covering different levels of healthcare organisations and reimbursement systems. Real world evidence (RWE) and payment evidence will be generated and provided to relative authorities for the support of health and reimbursement policy making, streamlising of clinical path management, and effective development of hierarchical medical system. 

The strategic collaboration includes a prospective COPD registry study and “New Breath, Constant Care” China Asthma Patient Management Project. The COPD registry study will cover 5,000 patients, and establish in depth understanding of COPD disease characteristics, disease evolution, disease management, as well as the evolvement in the treatment paradigm. The registry will also be able to measure COPD disease burden, and predict disease outcome in China. This could further help inform the future COPD disease management strategy in China. 

“New Breath, Constant Care” China Asthma Patient Management Project will lead different levels of hospitals across China to set up a national asthma management collaboration network and build a digital asthma management platform including asthma disease EHR, a patient database and management tools based upon APPs. The project aims at establishing and improving asthma disease management result through more standardized clinic information and pathway, better doctor/patient communication and long-term big data analysis. It is estimated that the project will cover at least 60,000 asthma patients into regular management in 3 years. 

Prof Rong-chang Chen, Head of GIRD, commented, through partnership with leading multi-national pharma companies like GSK, we would fully leverage the new  study concept and transformation of medical science to change the traditional model of diagnosis and treatment. The grass-root patients will benefit from advanced options of diagnosis and treatment, and academic evidence will be provided to support the policies of health and reimbursement, as well as personalised treatment strategy which will fit the grass-root healthcare. 

Chief of State Key Laboratory of Respiratory Disease, Academician Professor Nan-shan Zhong, commented, the significance of the programme is to fully leverage big-data analytical technology, improve the identifying capability of early disease signals, and realise early treatment and improve outcome. Meanwhile, it will enhance the integration of clinical medicine and basic medicine data and information, and upgrade transformation and application of medical science study, and to provide a clear direction and feasible approach for COPD and asthma personalised treatment. 

Thomas Willemsen, General Manager, GSK China Pharma & Vaccines, said, "GSK has rich experience in research and development of respiratory medicine globally. We believe the evolving healthcare reform situation in China calls for new and innovative approaches such as the generation of real world evidence, in which GSK is a world leader. Through this partnership with GIRD we hope to help generate valuable data to improve patients’ health across all regions of China. Importantly, we hope it can make a contribution to the process of improving grassroots health capabilities and a tired-healthcare system. Furthermore as a multinational pharmaceutical company headquartered in the U.K., we hope this project can be an important highlight in UK-China people-to-people cooperation promoting joint scientific collaboration.” 

Respiratory diseases are recognised by World Health Organisation as one of the four major diseases affecting the people’s health. In China, there are about 30 million asthma patients while the control rate is only 34.9%. COPD is also a common chronic disease in China. Latest epidemiology data shows that the mobidity rate of adults with COPD in China is 14%. Without more effectitve options of diagnosis, treatment and prevention, it would be very challenging to improve the situation that millions of patiants die from COPD every year. 

 

As part of the ‘in China, with China, for China’ strategy, GSK China has already:

  • The National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention and the aid of GSK, was officially kicked off in June 2017.
  • Joined hands with the Home of Red Ribbon to combat HIV/AIDS, unveiling plan to support people living with HIV in Nov 2016.
  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016.
  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016.
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.

 

 

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

 

GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.

 

GSK enquiries:

Susan Song            susan.s.song@gsk.com      (China)